Sarcoma News

PLX3397, a selective CSF1R inhibitor, demonstrated safety and activity in the treatment of patients with tenosynovial giant-cell tumor, according to study findings published in The New England Journal of Medicine.

Occult maternal malignancies may provide a biological explanation for some discordant non-invasive prenatal test results.

The FDA granted orphan drug designation to a formulation of dactinomycin for the treatment of children with Ewing’s sarcoma, according to a press release from the drug’s manufacturer.

Increased attention to the importance of informed decision making fosters physician and patient communication throughout cancer treatment.

The addition of pegylated interferon alfa-2b maintenance therapy to chemotherapy with methotrexate, doxorubicin and cisplatin did not statistically improves EFS in patients with osteosarcoma, according to the results of a phase 3 study.

The American Cancer Society estimates more than 589,000 Americans will die of cancer this year, making end-of-life conversations an inescapable reality for oncologists and other providers on their care teams.

CHICAGO — Long-term survivors of pediatric soft tissue sarcoma were at a nearly fourfold higher risk for chronic medical conditions compared with their siblings, according to findings presented at the ASCO Annual Meeting.

When the Affordable Care Act established an abbreviated licensure pathway for biosimilars in the United States, development of the agents accelerated at a staggering pace.

HemOnc Today’s annual Oncology Drugs in the Pipeline chart lists agents in phase 2 or phase 3 development for a variety of indications. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice.

 CHICAGO – The chemotherapy drug eribulin conferred a 2-month median OS improvement in previously treated patients with advanced intermediate or high grade liposarcoma or leiomyosarcoma compared with dacarbazine, according to results of a phase 3 trial presented at the ASCO Annual Meeting.